{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T09:17:15Z","timestamp":1787995035253,"version":"build-2784847793"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Peking Union Medical College Hospital Outstanding Young Talent Development Program","award":["UBJ10806"],"award-info":[{"award-number":["UBJ10806"]}]},{"name":"Beijing Key Clinical Specialty Program","award":["U113001"],"award-info":[{"award-number":["U113001"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["No. 2022-PUMCH-B-044"],"award-info":[{"award-number":["No. 2022-PUMCH-B-044"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s10067-026-08294-6","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T09:41:52Z","timestamp":1785231712000},"page":"5777-5786","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rapid and regular dose escalation in urate lowering therapy: a pragmatic clinical trial"],"prefix":"10.1007","volume":"45","author":[{"given":"Bingqing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingdong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6373-0647","authenticated-orcid":false,"given":"Yun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"issue":"1","key":"8294_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1136\/annrheumdis-2019-215315","volume":"79","author":"P Richette","year":"2020","unstructured":"Richette P, Doherty M, Pascual E, H et al (2020) 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis 79(1):31\u201338","journal-title":"Ann Rheum Dis"},{"key":"8294_CR2","doi-asserted-by":"crossref","unstructured":"Qaseem A, Harris RP, Forciea MA (2017) Clinical Guidelines Committee of the American College of Physicians. Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians. Ann Intern Med 166(1):58\u201368","DOI":"10.7326\/M16-0570"},{"issue":"3","key":"8294_CR3","doi-asserted-by":"publisher","first-page":"ITC33","DOI":"10.7326\/ANNALS-24-03951","volume":"178","author":"JD FitzGerald","year":"2025","unstructured":"FitzGerald JD (2025) Gout. Ann Intern Med 178(3):ITC33\u2013ITC48","journal-title":"Ann Intern Med"},{"issue":"6","key":"8294_CR4","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.24180","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T et al (2020) 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken) 72(6):744\u2013760","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"8294_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.o1754","volume":"378","author":"J Neilson","year":"2022","unstructured":"Neilson J, Bonnon A, Dickson A et al (2022) Gout: diagnosis and management-summary of NICE guidance. BMJ 378","journal-title":"BMJ"},{"issue":"5","key":"8294_CR6","first-page":"799","volume":"43","author":"L Punzi","year":"2025","unstructured":"Punzi L, Scagnellato L, Galozzi P et al (2025) Gout: one year in review 2025. Clin Exp Rheumatol 43(5):799\u2013808","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"8294_CR7","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1136\/annrheumdis-2013-204463","volume":"74","author":"CF Kuo","year":"2015","unstructured":"Kuo CF, Grainge MJ, Mallen C et al (2015) Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis 74(4):661\u2013667","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"8294_CR8","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1002\/art.40807","volume":"71","author":"M Chen-Xu","year":"2007","unstructured":"Chen-Xu M, Yokose C, Rai SK et al (2007) Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the national health and nutrition examination survey, 2007-2016. Arthritis Rheumatol 71(6):991\u2013999","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"8294_CR9","doi-asserted-by":"publisher","first-page":"e507","DOI":"10.1016\/S2665-9913(24)00117-6","volume":"6","author":"GBDG Collaborators","year":"2024","unstructured":"Collaborators GBDG (2024) Global, regional, and national burden of gout, 1990\u20132020, and projections to 2050: a systematic analysis of the global burden of disease study 2021. Lancet Rheumatol 6(8):e507\u2013e517","journal-title":"Lancet Rheumatol"},{"issue":"7","key":"8294_CR10","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1111\/bcp.15657","volume":"89","author":"JCJ Spragg","year":"2023","unstructured":"Spragg JCJ, Michael TJF, Aslani P et al (2023) Optimizing adherence to allopurinol for gout: patients\u2019 perspectives. Br J Clin Pharmacol 89(7):1978\u20131991","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"8294_CR11","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1002\/acr.24032","volume":"72","author":"A Kelly","year":"2020","unstructured":"Kelly A, Tymms K, de Wit M et al (2020) Patient and caregiver priorities for medication adherence in gout, osteoporosis and rheumatoid arthritis: nominal group technique. Arthritis Care Res (Hoboken) 72(10):1410\u20131419","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"8294_CR12","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1136\/annrheumdis-2017-211574","volume":"77","author":"H Yamanaka","year":"2018","unstructured":"Yamanaka H, Tamaki S, Ide Y et al (2018) Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study. Ann Rheum Dis 77(2):270\u2013276","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"8294_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.semarthrit.2014.01.004","volume":"44","author":"CG Jennings","year":"2014","unstructured":"Jennings CG, Mackenzie IS, Flynn R et al (2014) Up-titration of allopurinol in patients with gout. Semin Arthritis Rheum 44(1):25\u201330","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"8294_CR14","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1136\/annrheumdis-2016-210872","volume":"76","author":"LK Stamp","year":"2017","unstructured":"Stamp LK, Chapman PT, Barclay ML et al (2017) A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Ann Rheum Dis 76(9):1522\u20131528","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"8294_CR15","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208237","volume":"74","author":"T Neogi","year":"2015","unstructured":"Neogi T, Jansen TL, Dalbeth N et al (2015) 2015 Gout classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 74(10):1789\u20131798","journal-title":"Ann Rheum Dis"},{"key":"8294_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1565530","volume":"16","author":"X Zheng","year":"2025","unstructured":"Zheng X, Xie C, Fang J et al (2025) Efficacy of different dosages of common uric acid-lowering medications in gout patients: a network meta-analysis of randomized control trials. Front Pharmacol 16","journal-title":"Front Pharmacol"},{"issue":"13","key":"8294_CR17","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1001\/jama.2018.0547","volume":"319","author":"BM Kuehn","year":"2018","unstructured":"Kuehn BM (2018) Chronic disease approaches needed to curb gout\u2019s growing burden. JAMA 319(13):1307\u20131309","journal-title":"JAMA"},{"issue":"1","key":"8294_CR18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.7326\/M16-2401","volume":"166","author":"T Neogi","year":"2017","unstructured":"Neogi T, Mikuls TR (2017) To treat or not to treat (to target) in gout. Ann Intern Med 166(1):71\u201372","journal-title":"Ann Intern Med"},{"issue":"12","key":"8294_CR19","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1136\/ard-2023-224679","volume":"82","author":"H Xu","year":"2023","unstructured":"Xu H, Qin H, Hua Y et al (2023) Contributions of joint damage-related events to gout pathogenesis: new insights from laboratory research. Ann Rheum Dis 82(12):1511\u20131515","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"8294_CR20","doi-asserted-by":"publisher","first-page":"e156","DOI":"10.1016\/S2665-9913(23)00338-7","volume":"6","author":"LD Ferguson","year":"2024","unstructured":"Ferguson LD, Molenberghs G, Verbeke G et al (2024) Gout and incidence of 12 cardiovascular diseases: a case-control study including 152 663 individuals with gout and 709 981 matched controls. Lancet Rheumatol 6(3):e156\u2013e167","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"8294_CR21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.7326\/M16-0461","volume":"166","author":"PG Shekelle","year":"2017","unstructured":"Shekelle PG, Newberry SJ, FitzGerald JD et al (2017) Management of gout: a systematic review in support of an American College of Physicians Clinical Practice Guideline. Ann Intern Med 166(1):37\u201351","journal-title":"Ann Intern Med"},{"issue":"8","key":"8294_CR22","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1007\/s10067-019-04566-6","volume":"38","author":"CA Janssen","year":"2019","unstructured":"Janssen CA, Oude Voshaar MAH, Ten Klooster PM et al (2019) Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare. Clin Rheumatol 38(8):2233\u20132239","journal-title":"Clin Rheumatol"},{"issue":"10","key":"8294_CR23","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1002\/art.42927","volume":"76","author":"A Barry","year":"2024","unstructured":"Barry A, Helget LN, Androsenko M et al (2024) Comparison of gout flares with the initiation of treat-to-target allopurinol and febuxostat: a post-hoc analysis of a randomized multicenter trial. Arthritis Rheumatol 76(10):1552\u20131559","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"8294_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41584-019-0334-3","volume":"16","author":"LAB Joosten","year":"2020","unstructured":"Joosten LAB, Cri\u015fan TO, Bjornstad P et al (2020) Asymptomatic hyperuricaemia: a silent activator of the innate immune system. Nat Rev Rheumatol 16(2):75\u201386","journal-title":"Nat Rev Rheumatol"},{"issue":"23","key":"8294_CR25","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr., Wortmann RL et al (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353(23):2450\u201361","journal-title":"N Engl J Med"},{"key":"8294_CR26","doi-asserted-by":"crossref","unstructured":"Pryymachenko Y, Wilson R, Dalbeth N et al (2025) Cost-effectiveness of low dose colchicine prophylaxis when starting allopurinol using the \u201cstart-low go-slow\u201d approach for gout: evidence from a non-inferiority randomised double-blind placebo-controlled trial. Arthritis Care Res (Hoboken). https:\/\/doi.org\/10.1002\/acr.25631","DOI":"10.1002\/acr.25631"},{"issue":"3","key":"8294_CR27","doi-asserted-by":"publisher","first-page":"e156","DOI":"10.1016\/S2665-9913(23)00338-7","volume":"6","author":"LD Ferguson","year":"2024","unstructured":"Ferguson LD, Molenberghs G, Verbeke G et al (2024) Gout and incidence of 12 cardiovascular diseases: a case-control study including 152 663 individuals with gout and 709 981 matched controls. Lancet Rheumatol 6(3):e156\u2013e167. https:\/\/doi.org\/10.1016\/S2665-9913(23)00338-7","journal-title":"Lancet Rheumatol"},{"issue":"5","key":"8294_CR28","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1002\/art.27356","volume":"62","author":"N Dalbeth","year":"2010","unstructured":"Dalbeth N, Pool B, Gamble GD et al (2010) Cellular characterization of the gouty tophus: a quantitative analysis. Arthritis Rheum 62(5):1549\u20131556","journal-title":"Arthritis Rheum"},{"key":"8294_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.09.003","author":"H Xu","year":"2025","unstructured":"Xu H, Liu Z, Zhou X et al (2025) Deconstruction of tophi and synovium defines SPP1(+) macrophages involved in extracellular matrix remodelling in gout. Ann Rheum Dis. https:\/\/doi.org\/10.1016\/j.ard.2025.09.003","journal-title":"Ann Rheum Dis"},{"issue":"10156","key":"8294_CR30","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S0140-6736(18)32158-5","volume":"392","author":"M Doherty","year":"2018","unstructured":"Doherty M, Jenkins W, Richardson H et al (2018) Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet 392(10156):1403\u20131412","journal-title":"Lancet"},{"issue":"12","key":"8294_CR31","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.sapharm.2025.06.108","volume":"21","author":"M Tanveer","year":"2025","unstructured":"Tanveer M, Tahir AH, Shrestha S et al (2025) Effectiveness of pharmacist-led interventions in improving gout outcomes: a systematic review. Res Social Adm Pharm 21(12):975\u2013990","journal-title":"Res Social Adm Pharm"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08294-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08294-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08294-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T08:35:53Z","timestamp":1787992553000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08294-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["8294"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08294-6","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"25 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Declarations"}}]}}